英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

bristling    音标拼音: [br'ɪsəlɪŋ] [br'ɪslɪŋ]
n. 类似鲈的一种鱼

类似鲈的一种鱼

Bristle \Bris"tle\, v. t. [imp. & p. p. {Bristled}; p. pr. & vb.
n. {Bristling}.]
1. To erect the bristles of; to cause to stand up, as the
bristles of an angry hog; -- sometimes with up.
[1913 Webster]

Now for the bare-picked bone of majesty
Doth dogged war bristle his angry crest. --Shak.
[1913 Webster]

Boy, bristle thy courage up. --Shak.
[1913 Webster]

2. To fix a bristle to; as, to bristle a thread.
[1913 Webster]


请选择你想看的字典辞典：
单词字典翻译
bristling查看　bristling　在百度字典中的解释百度英翻中〔查看〕
bristling查看　bristling　在Google字典中的解释Google英翻中〔查看〕
bristling查看　bristling　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • New Medications for Type 2 Diabetes and Kidney Disease: SGLT2 . . .
    Learn about FDA-approved medications, SGLT2 inhibitors, Finerenone, and GLP-1 RA, that are effective for patients with type 2 diabetes and kidney disease or early-stage kidney disease
  • 9. Pharmacologic Approaches to Glycemic Treatment: Standards . . .
    When initiating intensification of insulin therapy, metformin, SGLT2 inhibitors, and GLP-1 RAs (or a dual GIP and GLP-1 RA) should be maintained, unless adverse effects (including significant treatment burden) or contraindications are present
  • Genitourinary Tract Infections in Patients Taking SGLT2 . . .
    Recognition of risk factors for sodium-glucose cotransporter 2 (SGLT2) inhibitor-associated genitourinary tract (GU) infections is essential in the prevention of GU infections before and during SGLT2 inhibitor therapy Modifiable risk factors such as glycemic control should be corrected or optimized eGFR = estimated glomerular filtration rate
  • SGLT2 Inhibitors: What They Are, Uses Side Effects
    SGLT2 inhibitors lower blood sugar by causing your kidneys to remove glucose through your pee Learn more about this treatment for Type 2 diabetes
  • The SGLT2 Diet: Eating to Support Your Diabetes Medication
    Food can either support your treatment or get in its way, and for people taking SGLT2 inhibitors, certain dietary choices can help maximize the benefits while reducing side effects
  • Sodium-Glucose Transport 2 (SGLT2) Inhibitors | Treatment . . .
    Point of Care - Clinical decision support for Sodium-Glucose Transport 2 (SGLT2) Inhibitors Treatment and management Indications, Mechanism of Action, Administration, Adverse Effects, Contraindications, Monitoring, Toxicity, Enhancing Healthcare Team Outcomes
  • SGLT2 Inhibitor Use in Chronic Kidney Disease: Supporting . . .
    Originally developed for use in type 2 diabetes mellitus (T2DM), sodium–glucose co-transporter-2 (SGLT2) inhibitors demonstrated diverse cardiovascular- and kidney-protective effects in large outcome trials Their subsequent approval as a treatment for chronic kidney disease (CKD) marked a pivotal shift in the landscape of CKD management Further to this, the approval of dapagliflozin and
  • 11. Chronic Kidney Disease and Risk Management: Standards of . . .
    Moreover, recent data support the notion that SGLT2 inhibitors reduce oxidative stress in the kidney by >50% and blunt increases in angiotensinogen as well as reduce NLRP3 inflammasome activity (92–94) Glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) have also been shown to improve kidney outcomes (95–100)
  • USE OF SGLT2 INHIBITORS IN THE MANAGEMENT OF PATIENTS WITH . . .
    is designed to provide practical guidance for clinicians on the implementation of sodium-glucose cotransporter-2 inhibitors (SGLT2i) into treatment of patients with heart failure
  • SGLT2 inhibitors in hemodialysis or peritoneal dialysis . . .
    A slightly but not significant higher incidence of adverse events was reported during empagliflozin treatment Beyond the cardiac benefits of SGLT2i that could theoretically support the use of these drugs in ESKD, in the subgroup of patients undergoing PD an additive effect on the peritoneal membrane should be considered based on experimental data





中文字典-英文字典  2005-2009